Sanofi - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SNY Nasdaq 2830 www.sanofi.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sanofi

Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study - Jun 29th, 2026 11:00 pm
Deutsche Bank Cuts PT on Sanofi (SNY) – Here’s Why - Jun 27th, 2026 1:10 pm
BofA Expects Positive Investor Reaction to Leadership Update at Sanofi (SNY) - Jun 26th, 2026 10:14 pm
Sanofi Faces EU Probe With Fines Possibly Reaching 10% - Jun 26th, 2026 11:38 am
Sanofi Faces EU Antitrust Probe Over Flu Vaccine Communication Campaign - Jun 26th, 2026 4:51 am
EU hits France's Sanofi with flu vaccine antitrust probe - Jun 26th, 2026 4:46 am
Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi? - Jun 25th, 2026 2:57 pm
Is AbbVie a Buy After Its Purchase of Apogee? - Jun 25th, 2026 8:13 am
REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan - Jun 25th, 2026 7:00 am
Press Release: Sanofi Foundation opens new chapter centered on future generations - Jun 25th, 2026 12:00 am
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight - Jun 24th, 2026 8:31 am
How Back‑to‑Back BTK Drug Approvals At Sanofi (ENXTPA:SAN) Has Changed Its Investment Story - Jun 24th, 2026 6:10 am
Sanofi (ENXTPA:SAN) Wins Two Drug Approvals In Japan And The EU - Jun 24th, 2026 5:12 am
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor - Jun 24th, 2026 2:12 am
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis - Jun 23rd, 2026 9:24 am
How Kardigan spun deal leftovers into a $400M IPO - Jun 23rd, 2026 4:21 am
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia - Jun 22nd, 2026 11:15 pm
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses - Jun 22nd, 2026 11:00 pm
DoH and Sanofi Partner to Advance Vaccine Innovation - Jun 22nd, 2026 5:46 pm
The $11 Billion Reason Abbvie Stock Is Up Today - Jun 22nd, 2026 2:53 pm